Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04690855
Title A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA) (TARA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mylin A. Torres, MD

triple-receptor negative breast cancer


Atezolizumab + Talazoparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.